The Effect of Nusinersen Therapy on Laboratory Parameters of Patients with Spinal Muscular Atrophy

 

 Permissions and Reprints

Abstract

Introduction We evaluated the effect of nusinersen on clinical and laboratory parameters and presented its safety and effect on laboratory parameters.

Methods Two groups were formed from among patients with spinal muscular atrophy (SMA) followed up between September 2017 and June 2021: group 1, SMA type 1; group 2, SMA type 2 and 3. The laboratory parameters were evaluated in groups 1 and 2 between doses. Motor scale tests were performed on patients before each dose of nusinersen.

Results Twenty seven patients (group 1; n = 13, group 2; n = 14) were included. The mean age (±standard deviation) at the onset of symptoms was 3 ± 1.21 (range, 1.5–6) months in group 1 and 12 ± 4.27 (range, 8–24) months in group 2. No significant laboratory treatment-related abnormalities and adverse effects were observed. The cerebrospinal fluid protein levels and the frequency of conventional LP were higher in group 1. Serum creatinine (Cr) levels were higher in group 1 before the first dose and higher in group 2 before the fifth dose (p < 0.05). With treatment, the Cr levels of group 1 decreased and group 2 remained constant or increased. We observed that the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders and Hammersmith Functional Motor Scale-Expand scores increased as our patients received treatment (p < 0.05).

Conclusion Our results support the safety and efficacy of nusinersen. However, changes in Cr levels according to the clinical type and treatment suggested that serum Cr could be a candidate marker for treatment follow-up.

Publication History

Received: 14 February 2022

Accepted: 05 May 2022

Article published online:
24 July 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

• References

• 1 Verhaart IEC, Robertson A, Wilson IJ. et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy—a literature review. Orphanet J Rare Dis 2017; 12 (01) 124
  CrossrefPubMedGoogle Scholar
• 2 Groen EJN, Talbot K, Gillingwater TH. Advances in therapy for spinal muscular atrophy: promises and challenges. Nat Rev Neurol 2018; 14 (04) 214-224
  CrossrefPubMedGoogle Scholar
• 3 Spinraza (package insert). Cambridge, MA: Biogen Inc; 2017
• 4 Haché M, Swoboda KJ, Sethna N. et al. Intrathecal injections in children with spinal muscular atrophy: nusinersen clinical trial experience. J Child Neurol 2016; 31 (07) 899-906
  CrossrefPubMedGoogle Scholar
• 5 Finkel RS, Chiriboga CA, Vajsar J. et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 2016; 388 (10063): 3017-3026
  CrossrefPubMedGoogle Scholar
• 6 Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010; 50: 259-293
  CrossrefPubMedGoogle Scholar
• 7 Chan JH, Lim S, Wong WS. Antisense oligonucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol 2006; 33 (5-6): 533-540
  CrossrefPubMedGoogle Scholar
• 8 Frazier KS. Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist's perspective. Toxicol Pathol 2015; 43 (01) 78-89
  CrossrefPubMedGoogle Scholar
• 9 Jason TL, Koropatnick J, Berg RW. Toxicology of antisense therapeutics. Toxicol Appl Pharmacol 2004; 201 (01) 66-83
  CrossrefPubMedGoogle Scholar
• 10 Stolte B, Nonnemacher M, Kizina K. et al. Nusinersen treatment in adult patients with spinal muscular atrophy: a safety analysis of laboratory parameters. J Neurol 2021; 268 (12) 4667-4679
  CrossrefPubMedGoogle Scholar
• 11 Goedeker NL, Gibbons JL, Varadhachary AS, Connolly AM, Zaidman CM. Laboratory monitoring of nusinersen safety. Muscle Nerve 2021; 63 (06) 902-905
  CrossrefPubMedGoogle Scholar
• 12 Crooke ST, Baker BF, Kwoh TJ. et al. Integrated safety assessment of 2′-o-methoxyethyl chimeric antisense oligonucleotides in nonhuman primates and healthy human volunteers. Mol Ther 2016; 24 (10) 1771-1782
  CrossrefPubMedGoogle Scholar
• 13 Crooke ST, Baker BF, Witztum JL. et al. The effects of 2′-o-methoxyethyl containing antisense oligonucleotides on platelets in human clinical trials. Nucleic Acid Ther 2017; 27 (03) 121-129
  CrossrefPubMedGoogle Scholar
• 14 Hegen H, Auer M, Zeileis A, Deisenhammer F. Upper reference limits for cerebrospinal fluid total protein and albumin quotient based on a large cohort of control patients: implications for increased clinical specificity. Clin Chem Lab Med 2016; 54 (02) 285-292
  CrossrefPubMedGoogle Scholar
• 15 McCudden CR, Brooks J, Figurado P, Bourque PR. Cerebrospinal fluid total protein reference intervals derived from 20 years of patient data. Clin Chem 2017; 63 (12) 1856-1865
  CrossrefPubMedGoogle Scholar
• 16 Garton MJ, Keir G, Lakshmi MV, Thompson EJ. Age-related changes in cerebrospinal fluid protein concentrations. J Neurol Sci 1991; 104 (01) 74-80
  CrossrefPubMedGoogle Scholar
• 17 Kahlmann V, Roodbol J, van Leeuwen N. et al. Validated age-specific reference values for CSF total protein levels in children. Eur J Paediatr Neurol 2017; 21 (04) 654-660
  CrossrefPubMedGoogle Scholar
• 18 Wurster CD, Koch JC, Cordts I. et al. Routine cerebrospinal fluid (CSF) parameters in patients with spinal muscular atrophy (SMA) treated with nusinersen. Front Neurol 2019; 10: 1179
  CrossrefPubMedGoogle Scholar
• 19 Müschen LH, Osmanovic A, Binz C. et al. Cerebrospinal fluid parameters in antisense oligonucleotide-treated adult 5q-spinal muscular atrophy patients. Brain Sci 2021; 11 (03) 296
  CrossrefPubMedGoogle Scholar
• 20 De Vivo DC, Bertini E, Swoboda KJ. et al; NURTURE Study Group. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord 2019; 29 (11) 842-856
  CrossrefPubMedGoogle Scholar
• 21 Finkel RS, Mercuri E, Darras BT. et al; ENDEAR Study Group. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 2017; 377 (18) 1723-1732
  CrossrefPubMedGoogle Scholar
• 22 Mercuri E, Darras BT, Chiriboga CA. et al; CHERISH Study Group. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med 2018; 378 (07) 625-635
  CrossrefPubMedGoogle Scholar
• 23 Kim SW, Jung HW, Kim CH, Kim KI, Chin HJ, Lee H. A new equation to estimate muscle mass from creatinine and cystatin C. PLoS One 2016; 11 (02) e0148495
  CrossrefPubMedGoogle Scholar
• 24 Alves CRR, Zhang R, Johnstone AJ. et al. Serum creatinine is a biomarker of progressive denervation in spinal muscular atrophy. Neurology 2020; 94 (09) e921-e931
  CrossrefPubMedGoogle Scholar
• 25 Freigang M, Wurster CD, Hagenacker T. et al. Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment. Ann Clin Transl Neurol 2021; 8 (05) 1049-1063
  CrossrefPubMedGoogle Scholar
• 26 Darras BT, Farrar MA, Mercuri E. et al. An integrated safety analysis of infants and children with symptomatic spinal muscular atrophy (SMA) treated with nusinersen in seven clinical trials. CNS Drugs 2019; 33 (09) 919-932
  CrossrefPubMedGoogle Scholar
• 27 Portuguese AJ, Rothberg A, Gorgone M, Strawderman M, Jacob C. Safety of bedside lumbar puncture in adult patients with thrombocytopenia. Ann Hematol 2020; 99 (08) 1755-1762
  CrossrefPubMedGoogle Scholar
• 28 Szabó L, Gergely A, Jakus R. et al. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: real world data from Hungarian patients. Eur J Paediatr Neurol 2020; 27: 37-42
  CrossrefPubMedGoogle Scholar
• 29 Szunyogova E, Zhou H, Maxwell GK. et al. Survival motor neuron (SMN) protein is required for normal mouse liver development. Sci Rep 2016; 6: 34635
  CrossrefPubMedGoogle Scholar
• 30 Celkan TT. What does a hemogram say to us?. Turk Pediatri Ars 2020; 55 (02) 103-116
  PubMedGoogle Scholar
• 31 Mercuri E, Lucibello S, Perulli M. et al. Longitudinal natural history of type I spinal muscular atrophy: a critical review. Orphanet J Rare Dis 2020; 15 (01) 84
  CrossrefPubMedGoogle Scholar
• 32 Coratti G, Lucibello S, Pera MC. et al; ISMAC group. Gain and loss of abilities in type II SMA: a 12-month natural history study. Neuromuscul Disord 2020; 30 (09) 765-771
  CrossrefPubMedGoogle Scholar
• 33 Osredkar D, Jílková M, Butenko T. et al. Children and young adults with spinal muscular atrophy treated with nusinersen. Eur J Paediatr Neurol 2021; 30: 1-8
  CrossrefPubMedGoogle Scholar